NCT06532006: An ongoing trial by Shanghai Henlius Biotech
This trial is ongoing. It must report results 2 years, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06532006 |
|---|---|
| Title | A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 22, 2024 |
| Completion date | June 1, 2027 |
| Required reporting date | May 31, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |